Back

Corrigendum to: PCSK9 inhibition in patients with heart failure – neutral or harmful intervention?

European Heart Journal

17 February 2022
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY HEART FAILURE Chronic Heart Failure BASIC SCIENCE Pharmacology and Pharmacotherapy
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibition and cardiovascular outcomes by heart failure status: a pooled analysis of SPIRE-1 and SPIRE-2
10 May 2026
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Congress Session
Editor's Choice: report from the heart failure sections of ESC Journal Family and overview of the ESC Textbook of Heart Failure
18 May 2025
thumbnail
Congress Presentation
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources